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Abstract
Background: A patient’s perception of how their glaucoma is managed will influence both adherence to their
medication and outcome measures such as quality of life.
Methods: Prospective consecutive study using a Glaucoma Patient-reported Outcome and Experience Measure
(POEM) modified for an Australian ophthalmic private clinical practice setting. The Australian Glaucoma POEM
consists of eight items related to the patient’s understanding of the diagnosis and management, acceptability of
the treatment, whether they feel their glaucoma is getting worse, interfering with their daily life and concerns
regarding loss of vision as well as addressing whether they feel safe under the care of their glaucoma team and
how well their care is organised.
Results: Two hundred and two patients (M:F 91:111) participated in the study. Mean ± standard deviation for
subject age was 69 ± 13 years. Patient’s overall perception of their treatment and outcome was favourable. Younger
patients felt their glaucoma interfered more with their daily lives and were more worried about losing vision from
glaucoma. The greater the number of medications in use, the more they felt their glaucoma was getting worse and
that glaucoma interfered with their daily lives. With all other variables accounted for by the multivariate linear
model, female patients more strongly agreed that they understood their glaucoma diagnosis and glaucoma
management. The patients with a severe visual defect in their worse eye, reported a greater perceived
understanding of their glaucoma diagnosis and management and that they felt that glaucoma had a greater
interference on their daily life. They were also more concerned about losing vision from glaucoma than their fellow
glaucoma patients with less severe or no visual field deficit in the worse eye.
Conclusions: The modified POEM demonstrates potential to capture the concerns of a practice’s glaucoma cohort
with a view to enhancing the quality of glaucoma care delivered.
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Background
Glaucoma is a leading cause of visual impairment worldwide
[1]. It has been dubbed “the silent thief of sight” because of
its insidious onset and potential progression to complete
blindness. Treatment needs to commence before patients
notice any visual changes, which poses significant challenges
to the patient in terms of adherence and tolerance [2–5].
The ocular medications required can be costly, irritate the
ocular surface, have systemic side-effects and escalation to
invasive surgical procedures may be necessary to prevent fur-
ther progression of vision loss. This may all occur despite
the patient still feeling asymptomatic [2–6]. Therefore a pa-
tient’s perception of how their disease is managed will influ-
ence both adherence and outcome measures such as quality
of life [7]. Many measurement tools have been developed
and validated for gauging patient reported outcomes and ex-
periences for a wide scope of diseases [8–10]. For this study,
the authors have adapted the Patient-reported Outcome and
Experience Measure (POEM) that was developed by Somner
et al. specifically for glaucoma, and applied it to a clinical
practice setting [11].
The Glaucoma POEM is a novel six-item questionnaire
that was developed from the “National Glaucoma Think
Tank” event in the United Kingdom in 2012 (Fig. 1). This
event was attended by 72 UK participants including 42 pa-
tients, 11 carers, 3 health workers and 15 ancillary staff.
These participants were divided in to “focus groups” for dis-
cussion lead by 23 health care professionals including oph-
thalmologists. Discussion was based around what type of
questions the participants would value in a glaucoma-specific
Patient-reported Outcome Measure (PROM) or Patient-re-
ported and Experience Measure (PREM). Narrative data
from the discussions was subjected to thematic analysis with
NVivo software, from which particular themes were ex-
tracted and sorted into PROM and PREM domains and sub-
categories. These were cross-referenced with existing generic
and vision-specific PROMs and PREMs, of which none were
found to sufficiently cover the domains and subcategories of
importance. The six-question patient-generated POEM was
derived from here, as a concise questionnaire that addressed
the areas of glaucoma experience and outcome of greatest
significance to the National Glaucoma Think Tank partici-
pants [11].
Prior to this study and to the authors knowledge, there
has not been a published account of clinical implemen-
tation of the POEM. The POEM is designed to be a pa-
tient-generated implement and in the planning phases of
application to a private ophthalmology setting in
Australia, the POEM underwent minor modifications for
enhanced situational and cultural appropriateness. The
resulting survey comprised eight questions, the response
for each to be marked on a Visual Analogue Scale
(VAS), as opposed to six items each requiring ordinal
categorical answer selection. We describe how imple-
mentation of the modified POEM is a useful tool in cap-
turing patient perceived experiences and outcomes as a
measure of quality in health care.
Methods
In order to be implemented in an Australian private practice,
the Glaucoma POEM underwent modification with input
from ophthalmic consultants, an optometric statistician and
an initial cohort of 25 patients. Patient input was voluntary
and obtained during routine consultations. The Australian
Glaucoma POEM consists of eight items related to the pa-
tient’s understanding of the diagnosis and management, ac-
ceptability of the treatment, whether they feel their glaucoma
is getting worse, interfering with their daily life and concerns
regarding loss of vision as well as addressing whether they
feel safe under the care of their glaucoma team and how well
their care is organised. Changes based on patient feedback
included wording alteration, with substitution of the
Fig. 1 Glaucoma POEM developed in the UK by Somner et al [11]
Fraenkel et al. BMC Ophthalmology          (2019) 19:192 Page 2 of 8
statement “I’m frightened of going blind from glau-
coma” with “I am not worried about losing vision
from glaucoma”, as the former was regarded by
many of our cohort as “overly emotive”. In the UK
Think Tank, fear of blindness was strongly expressed
and the changes implemented in this Australian set-
ting may reflect different disease complexity, models
of care and case-mix of the populations studied. The
Likert-type scale of the original Glaucoma POEM,
shown in Fig. 1, was modified into a VAS in order
to increase the quantitative analysis potential of the
study. In an earlier modification of the POEM with
the VAS, the orientation of the scale in the same
direction to the original POEM, yielded a number of
completion errors. It was decided that the scale
should be “strongly disagree” to the left and
“strongly agree” to the right, requiring the use of
“not” within questions 4–6. Although potentially
confusing, this change subsequently stopped the
completion errors. The VAS is used by other pa-
tient-reported outcome surveys such as European-
Quality of life 5-Dimensions score (EQ 5D) [12]. Fig-
ure 2 features the resulting modified POEM.
Two hundred and two consecutive glaucoma patients
were recruited from three private practices affiliated with
the City Eye Centre, Brisbane. Informed consent was ob-
tained from all patients. This study followed the tenets
of the Declaration of Helsinki and was approved by the
University of Queensland Human Research Ethics
Committee (approval number #2015000530). Patients
were included if they had a known diagnosis of glau-
coma, as confirmed by glaucoma subspecialist. They
were excluded if they had other visually significant ocu-
lar comorbidities.
The patient surveys were cross-referenced with their
files to collect data including patient age, gender, the
number of glaucoma medications currently in use, num-
ber of prior glaucoma surgeries, best-corrected visual
acuity (BCVA) in the worse eye on the day of survey
completion and their current visual field results (Hum-
phrey Field Analyser, Carl Zeiss AG, Oberkocken,
Germany) (Table 1).
The continuous patient variables for data analysis in-
cluded patient age, BCVA (converted to LogMAR) in
the worse eye and the number of glaucoma medications
used in the worse eye. The categorical variables used for
this study are listed below the continuous variables in
Table 2. Previous glaucoma surgery included trabecu-
lectomy, Molteno or Baerveldt tube insertion, selective
laser trabeculoplasty, cyclodiode laser or laser peripheral
iridotomy. Visual fields were categorically classified in
accordance to the Hodapp-Anderson-Parrish grading
scale where “mild” refers to a mean deviation (MD) of ≤
− 6 dB compared to an age matched population, “moder-
ate” equals > − 6 dB but <− 12 dB, and severe is ≥ − 12 dB
[13].
The outcome data was the patients’ marked scores on
the VAS, which was reported to whole numbers, with
Fig. 2 Australian Glaucoma POEM adapted from the UK POEM
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each VAS unit representing one mm on a 100 mm scale
(i.e. a score between 0 and 100). The questions were de-
signed so that the “strongly agree” end, hence VAS
scores closer to 100, reflected more positively perceived
experiences and outcomes. Statistical analysis was per-
formed with IBM SPSS Statistics Software (Version 22;
SPSS Inc., Chicago, IL, USA). Additionally, a linear
multivariate model was created to predict the VAS out-
come of each POEM question, with the patients’ demo-
graphic and disease characteristic variables as the
predictors. The results of the multivariate linear analysis
are reported in β coefficients and the corresponding 95%
CI. For the continuous predictors including patient age,
BCVA and number of glaucoma medications used, the β
coefficient can be defined as the variance in VAS score,
reported as a numerical increase or decrease in the VAS
score, that can be accounted for by a one unit increase
in the continuous variable. For the categorical predic-
tors, the β coefficient represents the variance in VAS
predicted when a subject belongs to the variable cat-
egory, where the “baseline” category is considered to
have no effect on the VAS score. The effect of a pre-
dictor, or variable, on the VAS score was considered to
be statistically significant if its β coefficient had a p-value
of <0.05.
Results
Two hundred and two patients (M:F 91:111) participated
in the study. Mean ± standard deviation for subject age
was 69 ± 13 years. Severe visual field loss (MD ≥ -12 dB)
was present in 75 (37%) (Table 1). The majority of the
cohort (184 patients, 91%) had primary open angle
glaucoma (POAG). Besides question 6 (“I don’t think
my glaucoma is getting worse”), the questions
yielded VAS with a strong right skew, indicating that
patient’s overall perception of their treatment and
outcome was favourable.
The results for the multivariate linear model are
displayed in Table 2. For the association between
patient age and response to question 1, regarding
the perceived understanding of their glaucoma diag-
nosis, the multivariate linear modelling gave a sta-
tistically significant β coefficient of − 0.2 (95% CI −
0.4 to 0.0, p = 0.03). This means that with all other
variables accounted for, an increase in age by one
unit (1 year) explains a variance in − 0.2 on the
VAS score, which would manifest as a mark 0.2 mm
closer to the “strongly disagree” end of the VAS;
that is the older the patient, the less their perceived
understanding of their diagnosis. A similar associ-
ation was evident for perceived understanding of
Table 1 Glaucoma cohort patient demographics and disease characteristics (n = 202)
Variable
Age (years) 69 ± 13 (range 24–94)
Gender Female 55%
Male 45%
Laterality of disease Unilateral 11%
Bilateral 89%
Glaucoma type POAG 91%
Other 9%
Previous glaucoma surgery None 58%
One eye 22%
Both eyes 20%
Other ocular surgery None 38%
Cataract surgery only 42%
Anterior surgery ± cataract surgery 6%
Vitreoretinal surgery ± cataract surgery 15%
Mean number of glaucoma medications 1.9 ± 1.1, range 0–4.5
Mean visual acuity (logMAR) Worse eye: 0.5 ± 0.8, range − 0.2 to 3.5
Better eye: 0.1 ± 0.3, range − 0.2 to 2.9
Visual field Worse eye
Normal 14%, Mild 26%, Moderate 23,37%
Better eye
Normal 29%, Mild 43%, Moderate 18%, Severe 10%
POAG Primary open angle glaucoma
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glaucoma management, but this did not reach stat-
istical significance (p = 0.08).
Age
There was a statistically significant association be-
tween patient age and perceived disease outcome as
per questions 5 and 6. Younger patients felt their
glaucoma interfered more with their daily lives (β
coefficient = 0.4, 95% CI - 0.1 to 0.8, p = 0.01) and
were more worried about losing vision from glau-
coma (β coefficient = 0.5, 95% CI -0.0 to 0.9, p =
0.04). No other significant associations were appar-
ent between age and the POEM responses.
BCVA in the worse eye
Although not reaching statistical significance, the more
severe loss of BCVA in the worse eye was consistently
associated with less favourable perceptions, for questions
1 to 6. This variable however, did not adversely affect
the patient experience of the treating team, in terms of
feeling safe under the team’s care or in the organisation
of care (β coefficient = 0, 95% CI − 2 to 2, p > 0.05 and β
coefficient 0, 95% CI − 2 to 1, p > 0.05 respectively).
Number of medications in the worse eye
A greater number of medications used in the worse eye
was associated with less favourable responses for most
of the POEM questions, but only significantly for ques-
tions 4 and 5. The greater the number of medications in
use, the more they felt their glaucoma was getting worse
(β coefficient = 3, 95% CI − 12 to 5, p = 0.005) and that
glaucoma interfered with their daily lives (β coefficient =
6, 95% CI − 10 to − 2, p = 0.002).
Gender
With all other variables accounted for by the multivari-
ate linear model, female patients more strongly agreed
that they understood their glaucoma diagnosis (β coeffi-
cient = 5, 95% CI - 0 to 10, p = 0.05) and glaucoma man-
agement (β coefficient = 6, 95% CI - 1 to 10, p = 0.01).
Previous glaucoma surgery
Compared to those patients with no history of glaucoma
surgery, those who had had bilateral glaucoma surgery
indicated that their glaucoma management was less ac-
ceptable to them (β coefficient = 8, CI − 16 to 0, p =
0.04) and that glaucoma interfered more with their daily
lives (β coefficient = 13, 95% CI − 25 to − 2, p = 0.03).
Other ocular surgery
Patients who had any other type of ocular surgery felt
glaucoma interfered with their daily lives as indicated by
the negative coefficients for all sub-categories. Only the
β coefficient for previous cataract surgery was statisti-
cally significant at − 13 (95% CI − 23 to − 3, p = 0.01).
Visual field in the worse eye
The patients with a severe visual defect in their worse
eye, reported a greater perceived understanding of their
glaucoma diagnosis and management (β coefficient = 9,
95% CI - 2 to 16, p = 0.02 and β coefficient = 8. 95% CI -
1 to 15, p = 0.03 respectively). and that they felt that
glaucoma had a greater interference on their daily life (β
coefficient = − 19, − 32 to − 9, p = 0.01). They were also
more concerned about losing vision from glaucoma (β
coefficient − 18, 95% CI − 32 to − 5) than their fellow
glaucoma patients with less severe or no visual field def-
icit in the worse eye.
Discussion
There are a number of patient-reported outcome and experi-
ence measures that have been applied to glaucoma [11, 14–
16]. The advantage of many of these pre-existing tools is that
they have been externally validated for reliability and
consistency. However, there are multiple factors that make
the available tools suboptimal for routine clinical implemen-
tation in glaucoma [11]. A number have been designed for
research purposes, with lengthy questionnaires, requiring ad-
ministration by trained personnel [11, 15, 17]. Other tools
are shorter, comprehensive and validated for a variety of dif-
ferent medical conditions, such as the howRUTM and the
EQ 5DR, however these have limited clinician accessibility
due to patents and cost [11, 18]. Overall, there is not an
established tool that has been optimised for use in routine
glaucoma clinical practice [11]. We propose the modified
POEM as a novel measure for gauging glaucoma patients’
perceived outcomes and experiences in one comprehensive
and clinically applicable tool.
The modified POEM has potential to be useful for glau-
coma patient feedback in clinical practice because it is de-
signed specifically for this purpose, and has been
developed with a “patient-generated” approach. Construc-
tion of the original POEM from focus groups means that
the survey addresses topics that are most pertinent to
glaucoma patients, and it can be customised to be more
culturally appropriate as we have done for this study [11].
Like those involved in the original POEM conception, the
patients involved in this POEM modification and imple-
mentation demonstrated willingness to participate and
perceived it as a positive exercise in patient involvement.
From a clinician’s perspective, the modified POEM is
practical for daily clinical use because it is simple, short
and provides quantitative data for comprehensive analysis.
This study demonstrates the detailed insight the POEM
can deliver on a patient cohort’s perception of their glau-
coma management and outcomes.
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The right skew of almost all VAS scores with medians
above 85 reflects an overall positive response to perceived
glaucoma experience and outcomes. Question 6 was the
only item with a median VAS score of below 50 and had
the widest interquartile range, reflecting a wide spread of
concern about losing vision from glaucoma. Questions 4
and 5 demonstrate the next largest quartile ranges. It can
be noted that Questions 4–6 are related to glaucoma out-
come. These results are reflective of the fact that the se-
verity of glaucoma can vary greatly between patients and
at different points of the disease process, ranging from im-
perceptible vision loss to blindness. Questions 7 and 8 re-
late to patients’ perception of their glaucoma experience
specific to the treating team, with the results suggesting
that patients in this cohort feel secure regardless of demo-
graphic or disease variables. The finding that previous
cataract surgery is associated with the perception that
glaucoma affects their daily lives more seems counterintu-
itive. One possibility is that cataract surgery is often asso-
ciated with improved vision, but if there is significant
glaucoma nerve damage, the vision may not be signifi-
cantly improved, with resulting disappointment regarding
the visual outcome. The non-linear relationship between
decline in vision-related quality of life (VRQL) and wors-
ening of the visual field is well documented. In earlier
stages of vision loss, there is slow decline in the VRQL,
however more rapid phase of change once the mean devi-
ation in the better eye worsens beyond -15 dB [3].
The responses to questions 1 and 2 demonstrate that
overall, this patient cohort strongly agreed with the state-
ment that they understand their glaucoma diagnosis and
management. Greater patient understanding of a medical
condition is linked with greater treatment adherence, in-
creased patient satisfaction and reduced anxiety [8, 9, 17].
The latter was shown in a recent Australian randomized
trial conducted by Skalicky et al. involving 101 newly-diag-
nosed glaucoma patients [19]. Half the patients received
standard care and counselling by their ophthalmologists
whilst the other half received an additional telephone
counselling session and glaucoma information mail out.
The second group was found to have a statistically signifi-
cant lower level of anxiety (− 0.60 logits, p = 0.02). They
also demonstrated an increase in knowledge to the control
group however this was not statistically significant (0.45
logits, p = 0.07) [19]. The approach for this study, was to
assess the patients’ perceived level of knowledge, as op-
posed to their actual level of knowledge.
This study suggested that the older the patient, the less
they understood their glaucoma diagnosis and how it
was managed (p = 0.03 and 0.08 respectively). However,
they did feel that the condition had less impact on their
daily lives and that they were less worried about losing
vision from glaucoma (p = 0.01 and p = 0.04). Younger
patients are more likely to be concerned about the potential
for loss of income-earning capacity and threat to their quality
of life over many years. They may subsequently be more mo-
tivated to ask questions regarding prognosis and seek re-
sources about glaucoma. These findings are consistent with
those from Odberg et al’s study involving 589 glaucoma sub-
jects in Norway who completed an in-depth survey investi-
gating the impact of glaucoma on quality of life [17]. Patients
younger than the age of 60 expressed a greater demand for
information and greater anxiety about their prognosis. This
suggests that younger patients may require more consult-
ation time and education materials. Newly diagnosed POAG
patients have been reported to understand their condition
better than those diagnosed more than 2 years, however lon-
ger diagnosed patients understood better their condition to
be long term [20].
The findings of this study are potentially limited to
this select private practice population of Caucasian, well-
educated and higher socio-economic patients. These pa-
tients were appreciative for the opportunity to complete
the study as they understood the importance of feed-
back, that would ultimately improve their own care. Fur-
ther studies using the POEM, would need to be adapted
accordingly to other population groups, with the com-
parative results of great interest, for example in a public
hospital outpatient setting. Other limitations of the modi-
fied POEM for clinical implementation include the re-
sources required in the administration of a paper survey
and recording the results. As noted by Øvretveit et al., a
successful patient perception measure should be simple to
integrate in to clinical workflow [9]. Some of these limita-
tions could be overcome by adaptation of the paper survey
in to an electronic format, potentially accessible via a
smartphone device. This would facilitate automatic data
collection and streamline data analysis. The duration of
the patient’s glaucoma may also have had an influence on
the POEM responses, however was not addressed in this
study. With further use of the POEM on a larger glau-
coma population, the validity, consistency and reliability
of the tool could be better evaluated. Follow up adminis-
tration of the POEM to the same population over time
also could detect whether changes to the system have
been effective in improving the quality of care [21].
Conclusion
The modified glaucoma POEM can provide detailed infor-
mation about a glaucoma cohort’s perception towards
their disease management experience and outcomes and
demonstrates advantages in implementation compared to
existing tools. It has potential to be useful for a means of
patient engagement and improvement in the delivery of
quality health care.
Abbreviations
BCVA: Best-corrected visual acuity; dB: Decibel; MD: Mean deviation;
POEM: Patient-reported Outcome and Experience Measure; PREM: Patient-
Fraenkel et al. BMC Ophthalmology          (2019) 19:192 Page 7 of 8
reported and Experience Measure; PROM: Patient-reported Outcome
Measure; VAS: Visual Analogue Scale
Acknowledgements
Not applicable.
Authors’ contributions
Made substantial contributions to conception and design, or acquisition of
data, or analysis and interpretation of data; AF, GL, SV, RV, RB, PS. Been
involved in drafting the manuscript or revising it critically for important
intellectual content; AF, GL, SV, RB, PS. Given final approval of the version to
be published. Each author should have participated sufficiently in the work
to take public responsibility for appropriate portions of the content; AF, GL,
SV, RV, RB, PS. Agreed to be accountable for all aspects of the work in
ensuring that questions related to the accuracy or integrity of any part of
the work are appropriately investigated and resolved. AF, GL, SV, RV, RB, PS
Funding
No sources of funding for the research reported.
Availability of data and materials
The datasets used and/or analysed during the current study are available
from the corresponding author on reasonable request.
Ethics approval and consent to participate
This study followed the tenets of the Declaration of Helsinki and was
approved by the University of Queensland Human Research Ethics
Committee (approval number #2015000530). Informed written consent was
obtained from all patients prior to completion of the POEM.
Consent for publication
Not Applicable.
Competing interests
The authors declare that they have no competing interests.
Author details
1City Eye Centre, 10/135 Wickham Terrace, Brisbane, Queensland 4000,
Australia. 2University of Queensland, Brisbane, Queensland, Australia.
3Queensland University of Technology, Brisbane, Australia. 4Cambridge
University Hospitals, Cambridge, UK. 5University Hospitals Birmingham NHS
Foundation Trust, Birmingham, UK. 6Institute of Ophthalmology, University
College London, London, UK. 7Centre for Health & Social Care Improvement,
University of Wolverhampton, Wolverhampton, UK.
Received: 6 November 2018 Accepted: 13 August 2019
References
1. Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of
glaucoma: a review. JAMA. 2014;311:1901–11.
2. Glen FC, Crabb DP. Living with glaucoma: a qualitative study of functional
implications and patients’ coping behaviours. BMC Ophthalmol. 2015;15:128.
3. Jones L, Bryan SR, Crabb DP. Gradually then suddenly? Decline in vision-
related quality of life as glaucoma worsens. J Ophthalmol. 2017;2017.
4. Sumi I, Shirato S, Matsumoto S, Araie M. The relationship between visual
disability and visual field in patients with glaucoma. Ophthalmology. 2003;
110:332–9.
5. Crabb DP. A view on glaucoma - are we seeing it clearly? Eye. 2016;30:304–
13.
6. Dunker S, Schmucker A, Maier H. Tolerability, quality of life, and persistency
of use in patients with glaucoma who are switched to the fixed
combination of latanoprost and timolol. Adv Ther. 2007;24:376–86.
7. Matsuura M, Hirasawa K, Hirasawa H, et al. Developing an item bank to
measure quality of life in individuals with glaucoma, and the results of the
interview with patients: the effect of visual function, visual field progression
rate, medical, and surgical treatments on quality of life. J Glaucoma. 2017;26:
e64–73.
8. Boiko O, Campbell JL, Elmore N, Davey AF, Roland M, Burt J. The role of
patient experience surveys in quality assurance and improvement: a focus
group study in English general practice. Health Expect. 2015;18:1982–94.
9. Øvretveit J, Zubkoff L, Nelson EC, Frampton S, Knudsen JL, Zimlichman E.
Using patient-reported outcome measurement to improve patient care. Int
J Qual Health Care. 2017;29:874–9.
10. Skalicky SE, Lamoureux EL, Crabb DP, Ramulu PY. Patient-reported
outcomes, functional assessment, and utility values in glaucoma. J
Glaucoma. 2019;28:89–96.
11. Somner JEA, Sii F, Bourne RR, Cross V, Burr JM, Shah P. Moving from PROMs
to POEMs for glaucoma care: a qualitative scoping exercise. Invest
Ophthalmol Vis Sci. 2012;53:5940–7.
12. van Reenen M, Janssen B. EQ-5D-5L user guide: basic information on how
to use the EQ-5D-5L instrument. The Netherlands: EuroQol Ressearch
Foundation; 2015.
13. Hodapp E, Richard K. Parrish II, Anderson DR. Clinical descisions in
glaucoma. St Louis: The CV Mosby Co; 1993.52–61.
14. Wilson MR, Coleman AL, Yu F, et al. Functional status and well-being in
patients with glaucoma as measured by the medical outcomes study short
Form-36 questionnaire. Ophthalmology. 1998;105:2112–6.
15. Che Hamzah J, Burr JM, Ramsay CR, Azuara-Blanco A, Prior M. Choosing
appropriate patient-reported outcomes instrument for glaucoma research: a
systematic review of vision instruments. Qual Life Res. 2011;20:1141–58.
16. Bozzani FM, Alavi Y, Jofre-Bonet M, Kuper H. A comparison of the sensitivity
of EQ-5D, SF-6D and TTO utility values to changes in vision and perceived
visual function in patients with primary open-angle glaucoma. BMC
Ophthalmol. 2012;12:43.
17. Odberg T, Jakobsen JE, Hultgren SJ, Halseide R. The impact of glaucoma on
the quality of life of patients in Norway. I. Results from a self-administered
questionnaire. Acta Ophthalmol Scand. 2001;79:116–20.
18. Benson T, Potts HW, Whatling JM, Patterson D. Comparison of howRU and
EQ-5D measures of health-related quality of life in an outpatient clinic.
Inform Prim Care. 2013;21:12–7.
19. Skalicky SE, Mellow G, House P, Fenwick E. Glaucoma Australia educational
impact study: a randomized short-term clinical trial evaluating the
association between glaucoma education and patient knowledge, anxiety
and treatment satisfaction. Clin Exp Ophthal. 2018;46:222–31.
20. McDonald L, Boodhna T, Ajtony C, Turnbull P, Bourne RRA, Crabb DP. Illness
perceptions in people newly diagnosed with glaucoma and ocular
hypertension. Br J Ophthalmol 2019 May 11. [Epub ahead of print].
21. Mc Donald L, Glen FC, Taylor DJ, Crabb DP. Self-momitoring symptoms in
glaucoma: a feasibility study of a web-based diary tool. J Ophthalmol. 2017;
2017:8452840.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Fraenkel et al. BMC Ophthalmology          (2019) 19:192 Page 8 of 8
